The FDA has approved an autoinjector formulation of Zilbrysq, a complement inhibitor for the treatment of generalized myasthenia gravis.

While the national burden of pediatric-onset multiple sclerosis is stable, regional incidence and disability rates are increasing in some states.

Starting disease-modifying therapy within 90 days of a neuromyelitis optica spectrum disorder attack may improve long-term disability recovery.

Eden Brothers, Home Grown, and Gardeners Basics are recalling certain lots and brands of broccoli seeds following potential salmonella contamination.

Dexmedetomidine administration is rising in opioid use disorder-related hospitalizations due to medetomidine appearing in illicit fentanyl.

Slowly expanding lesions account for a minority of T2 lesions but are found in most patients with multiple sclerosis across various subtypes.

Women with polyendocrine metabolic ovarian syndrome have an elevated risk for Alzheimer disease driven by metabolic dysfunction.

The FDA has cleared Motivista, the first prescription digital therapeutic indicated to treat negative symptoms of ...

Fast-acting and well tolerated, intranasal sufentanil-ketamine seems to be safe and effective for managing acute pediatric pain in the ED.

Laxative misuse and dietary restriction in bulimia nervosa are associated with specific structural brain changes including lower hippocampal volume.

Higher levels of exhaled carbon monoxide are linked to a decreased risk for Parkinson disease in adults without a history of smoking.

Patients with incident ischemic stroke who are exposed to higher levels of transportation noise may face an increased risk for stroke recurrence.